References
- van den Nieuwenhof L, Schermer T, Bosch Y, et al. Is physician-diagnosed allergic rhinitis a risk factor for the development of asthma? Allergy. 2010;65(8):1049–1055.
- Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160.
- Andersson M, Greiff L, Ojeda P, et al. Barrier-enforcing measures as treatment principle in allergic rhinitis: a systematic review. Curr Med Res Opin. 2014;30(6):1131–1137.
- Braunstahl GJ. United airways concept: what does it teach us about systemic inflammation in airways disease? Proc Am Thorac Soc. 2009;6(8):652–654.
- Cruz AA, Popov T, Pawankar R, et al. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy. 2007;62(Suppl 84):1–41.
- Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(5 Suppl):S147–S334.
- Klimek L, Gene-Schneider S, Mösges R, et al. Die ‘Pollenschutzcreme’ SIMAROline ist wirkungslos bei saisonalen allergischen Rhinitis. Allergologie. 2000;23:455–460.
- Olze H, Wustrow TP, Grigorov A. Provokationstest mit Immerfit Pollenschutzcreme bei Patienten mit allergischer Rhinitis. Originalia Erfahrungsheilkunde (Heidelb). 2002;51:S416–S421.
- Schwetz S, Olze H, Melchisedech S, et al. Efficacy of pollen blocker cream in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg. 2004;130(8):979–984.
- Geisthoff UW, Blum A, Rupp-Classen M, et al. Lipid-based nose ointment for allergic rhinitis. Otolaryngol Head Neck Surg. 2005;133(5):754–761.
- Geisthoff UW, Rupp-Classen M, Blum A, et al. [The use of lipid containing nasal ointment for allergic rhinitis–a therapeutic option? A bicentric, prospective, open, randomised, controlled clinical study]. Hno. 2005;53(12):1047–1050.
- Andersson M, Greiff L, Wollmer P. Nasal treatment with a microemulsion reduces allergen challenge-induced symptoms and signs of allergic rhinitis. Acta Otolaryngol. 2008;128(6):666–669.
- Ojeda P, Pique N, Alonso A, et al. A topical microemulsion for the prevention of allergic rhinitis symptoms: results of a randomized, controlled, double-blind, parallel group, multicentre, multinational clinical trial (Nares study). Allergy Asthma Clin Immunol. 2013;9(1):32.
- Bohm M, Avgitidou G, El Hassan E, et al. Liposomes: a new non-pharmacological therapy concept for seasonal-allergic-rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2012;269(2):495–502.
- Cingi C, Unlu HH, Songu M, et al. Seawater gel in allergic rhinitis: entrapment effect and mucociliary clearance compared with saline. Ther Adv Respir Dis. 2010;4(1):13–18.
- Paz Lansberg M, DeTineo M, Lane J, et al. A clinical trial of a microcrystalline cellulose topical nasal spray on the acute response to allergen challenge. Am J Rhinol Allergy. 2016;30(4):269–273.
- Klimek L, Mullol J, Hellings P, et al. Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. Expert Opin Pharmacother. 2016;17(5):657–669.
- Phadtare D, Phadtare G, Nilesh B, et al. Hypromellose – a choice of polymer in extended release tablet formulation. World J Pharmacy Pharmaceut Sci. 2014;3(9):551–566.
- Available from: www.nasaleze.com. cited 2017 Apr 17
- Burdock GA. Safety assessment of hydroxypropyl methylcellulose as a food ingredient. Food Chem Toxicol. 2007;45(12):2341–2351.
- Bouic PJD. A review of the efficacy and safety of nasaleze in the prevention and management of allergic rhinitis. Open Allergy J. 2008;1:1–4.
- Josling P, Steadman S. Use of cellulose powder for the treatment of seasonal allergic rhinitis. Adv Ther. 2003;20(4):213–219.
- Emberlin JC, Lewis RA. A double blind, placebo controlled trial of inert cellulose powder for the relief of symptoms of hay fever in adults. Curr Med Res Opin. 2006;22(2):275–285.
- Aberg N, Dahl A, Benson M. A nasally applied cellulose powder in seasonal allergic rhinitis (SAR) in children and adolescents; reduction of symptoms and relation to pollen load. Pediatr Allergy Immunol. 2011;22(6):594–599.
- Aberg N, Ospanova ST, Nikitin NP, et al. A nasally applied cellulose powder in seasonal allergic rhinitis in adults with grass pollen allergy: a double-blind, randomized, placebo-controlled, parallel-group study. Int Arch Allergy Immunol. 2014;163(4):313–318.
- Popov TA, Emberlin JC, Aberg N. A double blind placebo controlled study documenting the effect of nasally applied cellulose-derived powder in subjects sensitized to grass pollen. J Allergy Clin Immunology. 2017;139(2):AB386.
- Diethart B, Emberlin JC, Lewis RA. Hydroxypropylmethylcellulose gel application delays Der p 1 diffusion in vitro. Nat Sci. 2010;2(2):79–84.
- Emberlin JC, Lewis RA. A double blind, placebo-controlled cross over trial of cellulose powder by nasal provocation with Der p1 and Der f1. Curr Med Res Opin. 2007;23(10):2423–2431.
- Zakharzhevskaya TV, Sidorenko IV, Treskunov VK, et al. Efficiency and safety of nasal spray NASAVAL for prevention and treatment of perennial allergic rhinitis. Rossiyskiy Allergologicheskiy J. 2009;(5):82–86.
- Geppe NA, Snegotskaya MN, Kolosova NG, et al. Microdisperse cellulose powder for prevention of allergic rhinitis in children. Rossiyskiy Allergologicheskiy J. 2010;(4):73–78.
- Angotoyeva IB, Sukhovetchenko YV. Study of the effects of inert cellulose powder on the nasal mucosa. Rossiyskiy Allergologicheskiy J. 2011;(6):53–57.
- Penechko EM, Sizyakina LP. The efficiency of cellulose powder extract in complex therapy of patients with pollen allergic rhinitis. Rossiyskiy Allergologicheskiy J. 2011;(3):101–104.
- Zakharzhevskaya TV, Sidorenko IV, Treskunov VK, et al. Usage of new nasal sprey nasaval for the treatment and prevention of allergic rhinitis. Rossiyskiy Allergologicheskiy J. 2009;(4):82–86.
- Ilina N, Kurbacheva O, Mikeladse K, et al. Treatment and preventive action of nasal spray Nazaval in the allergic rhinitis patients Сlinical researches review. Rossiyskiy Allergologicheskiy J. 2011;(2):73–80.
- Minov JB, Karadzinska-Bislimovska J, Petrova T, et al. Inert cellulose powder in the treatment of seasonal allergic rhinitis. J Pulm Respir Med. 2017.
- Wan L, Li P. [Clinical efficacy of nasal cellulose powder for the treatment of allergic rhinitis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015;29(15):1340–1342.
- Valerieva A, Popov TA, Staevska M, et al. Effect of micronized cellulose powder on the efficacy of topical oxymetazoline in allergic rhinitis. Allergy Asthma Proc. 2015;36(6):e134–e139.
- Popov TA, Valerieva A, Church M, et al. Real-life study on the effect of micronized cellulose powder as add-on to intranasal as-needed treatment of subjects with pollen allergic rhinitis. J Allergy Clin Immunology. 2016;137(2):AB402.
- Valerieva A, Church MK, Staevska M, et al. Micronized cellulose powder as a means to enhance intranasal symptoms-driven treatment: patients’ attitudes in a real life setting. Allergy. 2016;71(Supplement 102):13.
- Brozek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Jun 8. pii: S0091-6749(17)30919-3.[Epub ahead of print].
- Lake CF. Rhinitis medicamentosa. Proc Staff Meet Mayo Clin. 1946;21(19):367–371.
- Graf P. Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity. Rhinology. 1996;34(1):9–13.
- Mortuaire G, de Gabory L, Francois M, et al. Rebound congestion and rhinitis medicamentosa: nasal decongestants in clinical practice. Critical review of the literature by a medical panel. Eur Ann Otorhinolaryngol Head Neck Dis. 2013;130(3):137–144.
- Hellings PW, Fokkens WJ, Bachert C, et al. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - a EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017;72:1297–1305.
- Berger WE, Meltzer EO. Intranasal spray medications for maintenance therapy of allergic rhinitis. Am J Rhinol Allergy. 2015;29(4):273–282.
- Bousquet J, Bachert C, Bernstein J, et al. Advances in pharmacotherapy for the treatment of allergic rhinitis; MP29-02 (a novel formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) fills the gaps. Expert Opin Pharmacother. 2015;16(6):913–928.
- Prenner BM. A review of the clinical efficacy and safety of MP-AzeFlu, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate, in clinical studies conducted during different allergy seasons in the US. J Asthma Allergy. 2016;9:135–143.
- Scadding G, Price D, El-Shanawany T, et al. Multicentre, non-interventional study to assess the profile of patients with uncontrolled rhinitis prescribed a novel formulation of azelastine hydrochloride and fluticasone propionate in a single spray in routine clinical practice in the UK. BMJ Open. 2017;7(4):e014777.